Advanced

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer

Josefsson, Andreas; Linder, Anna LU ; Flondell Site, Despina LU ; Canesin, Giacomo LU ; Stiehm, Anna LU ; Anand, Aseem LU ; Bjartell, Anders LU ; Damber, Jan-Erik and Welén, Karin (2017) In Prostate 77(8). p.849-858
Abstract

BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression. RESULTS: At inclusion, 46 out of 53 patients (87%) were CTC-positive with a... (More)

BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression. RESULTS: At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression-free survival, whereas PSA and alkaline phosphatase serum levels, Gleason score, or T-stage were not. EGFR-positive patients had significantly shorter time to progression (5 months) compared to EGFR-negative patients (11 months) (P < 0.05). CONCLUSIONS: In this explorative study, CTCs were detected in 98% of M1 patients and detection of EGFR in CTCs was strongly associated with poor outcome, which indicated that phenotypical analysis of CTC could be a promising prognostic marker of ADT-response in castration-naïve metastatic PC patients. Prostate 77:849–858, 2017. © 2017 Wiley Periodicals, Inc.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
androgen deprivation therapy, CTC, epidermal growth factor receptor
in
Prostate
volume
77
issue
8
pages
10 pages
publisher
John Wiley & Sons
external identifiers
  • scopus:85018738566
  • wos:000399884100004
ISSN
0270-4137
DOI
10.1002/pros.23325
language
English
LU publication?
yes
id
4bf07884-b60b-496b-95dd-5f7e41d38503
date added to LUP
2017-06-07 16:31:16
date last changed
2017-09-18 11:39:09
@article{4bf07884-b60b-496b-95dd-5f7e41d38503,
  abstract     = {<p>BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) &gt;80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression. RESULTS: At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression-free survival, whereas PSA and alkaline phosphatase serum levels, Gleason score, or T-stage were not. EGFR-positive patients had significantly shorter time to progression (5 months) compared to EGFR-negative patients (11 months) (P &lt; 0.05). CONCLUSIONS: In this explorative study, CTCs were detected in 98% of M1 patients and detection of EGFR in CTCs was strongly associated with poor outcome, which indicated that phenotypical analysis of CTC could be a promising prognostic marker of ADT-response in castration-naïve metastatic PC patients. Prostate 77:849–858, 2017. © 2017 Wiley Periodicals, Inc.</p>},
  author       = {Josefsson, Andreas and Linder, Anna and Flondell Site, Despina and Canesin, Giacomo and Stiehm, Anna and Anand, Aseem and Bjartell, Anders and Damber, Jan-Erik and Welén, Karin},
  issn         = {0270-4137},
  keyword      = {androgen deprivation therapy,CTC,epidermal growth factor receptor},
  language     = {eng},
  month        = {06},
  number       = {8},
  pages        = {849--858},
  publisher    = {John Wiley & Sons},
  series       = {Prostate},
  title        = {Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer},
  url          = {http://dx.doi.org/10.1002/pros.23325},
  volume       = {77},
  year         = {2017},
}